Fast-growing R&D services outfit WuXi PharmaTech is marching ahead with plans to wrap a $250 million venture fund aimed at U.S. and China life sciences companies. WuXi filed documents with the SEC last week outlining the goal for WuXi Healthcare Ventures Fund II, which it’s already made a $50 million anchor investment in. …read more […]
Sarepta, jockeying with rival BioMarin to commercialize a treatment for Duchenne muscular dystrophy, is looking to buy up complementary assets to fortify its position. But the company’s better-funded competitor believes its long history in rare disease R&D will give it a leg up as the pair move toward make-or-break FDA decisions. …read more Source: Sarepta […]
Clarus Ventures has unveiled a lead role in funding a startup, San Francisco-based Nuvelution Pharma, that has an eminent group of Big Pharma veterans on the board as it sets out to ink a few clinical trial deals with the industry. …read more Source: Risk-sharing trial ops group Nuvelution debuts with powerhouse board and backers […]
The year’s 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013’s top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma’s macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index. …read more […]
Neos Therapeutics spelled out the terms of its pending IPO, lining up for as much as $73.6 million as it moves forward with reformulated versions of common ADHD treatments. …read more Source: Neos angles for a $74M IPO to fund its ADHD drugs
G. Steven Burrill has landed in a fresh tub of hot water over allegations he embezzled millions of dollars from a biotech fund he ran–a year after one of his former staffers filed suit claiming that more than $20 million was diverted, which in turn prompted the fund’s institutional investors to boot the venture exec […]
Moving on from a painful Phase II failure for its top prospect, Ohr Pharmaceutical heralded new hope for the eye drop in retinal vein occlusion thanks to some positive results from a midstage study. …read more Source: Ohr rebounds from a costly failure with positive eye drop data
Otsuka and its partner Lundbeck snagged an FDA approval for Rexulti (brexpiprazole) to treat schizophrenia and as an add-on therapy for major depression, leaving the two companies prepping for an August launch into an increasingly crowded field. …read more Source: As schizophrenia rivals rush in, Otsuka and Lundbeck gain FDA OK for Rexulti
Anacor Pharmaceuticals’ topical treatment for eczema came through with positive results in a pair of Phase III trials, propelling the biotech’s shares upward and setting the stage for an FDA application next year. …read more Source: Anacor soars as its eczema cream succeeds in Phase III
